Tectonic Therapeutics
TECXTectonic Therapeutic is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs).
Earnings
Next report
Nov 5, 2026 (in 3 months)Valuation & ratios
Competitors
By market cap
Profile
Tectonic Therapeutic is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs). Utilizing its proprietary GEODe™ technology platform, the company aims to overcome historical challenges in GPCR-targeted biologic discovery to address significant unmet medical needs in cardiovascular and fibrotic diseases. The company's core value proposition lies in engineering biologics that offer superior selectivity and multi-modal action compared to traditional small-molecule drugs.
A clinical-stage innovator utilizing a proprietary platform to target GPCRs with biologics, a field traditionally dominated by small molecules.
FAQ
- What is Tectonic Therapeutics's market cap?
- Tectonic Therapeutics (TECX) has a market capitalization of $639.5M and trades on XNAS.
- Who are Tectonic Therapeutics's competitors?
- Tectonic Therapeutics's key competitors include Septerna, Alnylam Pharmaceuticals, GT Biopharma Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Tectonic Therapeutics partner with?
- Tectonic Therapeutics's notable partners include Harvard College, Novotech (Australia) Pty Limited, WuXi Biologics.
- What subsidiaries does Tectonic Therapeutics have?
- Tectonic Therapeutics's subsidiaries include Tectonic Operating Company, Inc..
- Where is Tectonic Therapeutics headquartered?
- Tectonic Therapeutics is headquartered in United States of America. It has been publicly traded since 2024.